Get Live Data

Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Destiny Pharma. Share Price
  4. Destiny Pharma. Share Regulatory News
  5. Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Destiny Pharma. Information

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.226%)
Open: 15.75
High: 15.75
Low: 15.75
Prev. Close: 15.75
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

21 Nov 2022 14:20

Destiny Pharma PLC Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections 21.11.2022 / 15:19 CET/CEST The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

News Source: News Direct

21.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language:English
Company:Destiny Pharma PLC
United States
ISIN:GB00BDHSP575
EQS News ID:1492837
 
End of NewsEQS News Service

1492837 21.11.2022 CET/CEST

corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

12345
Date   Source Headline
7th Dec 20227:00 amRNSFDA/CDC highlight need for infection preventions
7th Dec 20227:00 amRNSXF-73 Nasal final Phase 3 development plans
2nd Dec 20222:48 pmRNSDirector Disclosure
23rd Nov 20227:00 amRNSAppointment of Corporate Broker
21st Nov 20222:20 pmEQSDestiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
18th Nov 20221:16 pmRNSDirector Shareholding Amendment
15th Nov 20227:00 amRNSXF-73 advances to clinically enabling safety study
31st Oct 202211:06 amRNSSecond Price Monitoring Extn
31st Oct 202211:01 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSNotice of R&D Update Meeting
8th Sep 20227:00 amRNSInterim results for six months ended 30 June 2022
7th Sep 20227:03 amRNSPresenting at HC Wainwright Investment Conference
7th Sep 20227:01 amRNSPositive update from EMA on NTCD-M3 Phase 3 plans
5th Sep 20222:15 pmRNSExpiry of Share Options
22nd Aug 20227:00 amRNSNotice of Interim Results
28th Jul 20227:00 amRNSChair’s Investor Update
26th Jul 20227:00 amRNSPublication of new data on NTCD-M3
19th Jul 20227:00 amRNSPositive update from US FDA on XF-73 Phase 3
12th Jul 20227:00 amRNSGrant from the Cystic Fibrosis Foundation
7th Jul 20227:00 amRNSPublication of XF-73 drug synergy data
5th Jul 20227:00 amRNSNew XF-73 research programme
8th Jun 20227:00 amRNSGrant of share options
27th May 202211:56 amRNSResult of Annual General Meeting & Strategy Update
26th May 20227:00 amRNSBoard Changes
12th May 20227:00 amRNSLandmark NTCD-M3 data to be presented at Anaerobe
3rd May 20227:00 amRNSDestiny Pharma appoints Dr Yuri Martina as CMO
27th Apr 20223:34 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 20223:30 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSAudited results for year ended 31 December 2021
4th Apr 20222:45 pmRNSNotice of Results
4th Apr 20222:37 pmRNSNotification of Major Holdings
31st Mar 20227:00 amRNSTo present data at ECCMID Congress
28th Mar 202211:30 amRNSResult of General Meeting and Total Voting Rights
25th Mar 20227:00 amRNSResult of Open Offer
22nd Mar 202210:30 amRNSExercise of Options and Total Voting Rights
8th Mar 202212:30 pmRNSFundraising
8th Feb 20227:00 amRNSPositive feedback from EMA on XF-73 Nasal gel Ph 3
1st Feb 20224:11 pmRNSExercise of Options and Total Voting Rights
1st Feb 20227:00 amRNSPositive data in XF-73 Dermal study with NIAID
31st Jan 20222:30 pmRNSExercise of Options and Total Voting Rights
25th Jan 20227:00 amRNSGrant of share options
24th Jan 20227:00 amRNSClinical and commercial opportunity of NTCD-M3
21st Jan 20227:15 amRNSDestiny Pharma Lancet Report
17th Jan 20227:00 amRNSStrategy/Company/Ops Update
21st Dec 20214:35 pmRNSExercise of Options and Total Voting Rights
17th Dec 20219:46 amRNSGrant of share options
15th Nov 20212:26 pmRNSDirectorate Change
4th Nov 20217:00 amRNSSAB Member Prof. Gerding is Keynote at C.diff Conf
18th Oct 20217:00 amRNSStudy gives strong support for potential of XF-73
27th Sep 20213:18 pmRNSDirector/PDMR Shareholding
12345

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.